We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 28, 2021

Teclistamab in Patients With Relapsed or Refractory Multiple Myeloma

The Lancet


Additional Info

The Lancet
Teclistamab, a B-Cell Maturation Antigen × CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Multiple Myeloma (MajesTEC-1): A Multicentre, Open-Label, Single-Arm, Phase 1 Study
Lancet 2021 Aug 10;[EPub Ahead of Print], SZ Usmani, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, L Rosinol, A Chari, M Bhutani, L Karlin, L Benboubker, L Pei, R Verona, S Girgis, T Stephenson, Y Elsayed, J Infante, JD Goldberg, A Banerjee, MV Mateos, A Krishnan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading